Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors- March 2008 update

Revista Portuguesa de Pneumologia

Volumn 14, Issue 2, 2008, Pages 271-283

  Fonseca, João Eurico ^a   Lucas, Helena ^b   Canhão, Helena ^a   Duarte, Raquel ^b   Santos, Maria José ^a   Villar, Miguel ^b   Faustino, Augusto ^a   Raymundo, Elena ^b  

^a PortugueseSociety of Diabetology   (Portugal)

^b Tuberculosis Committee of the Portuguese Society of Pulmonology   (Portugal)

Author keywords

Anti TNF drugs; Guidelines; Portuguese society of pulmonology; Portuguese society of rheumatology; Tuberculosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETHAMBUTOL; ISONIAZID; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; STEROID; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTHRITIS; ARTICLE; CLINICAL PROTOCOL; HUMAN; IMMUNE DEFICIENCY; LATENT TUBERCULOSIS INFECTION; LUNG TUBERCULOSIS; MEDICAL SOCIETY; POSTPRIMARY TUBERCULOSIS; RISK BENEFIT ANALYSIS; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

EID: 42349083756     PISSN: 08732159     EISSN: None     Source Type: Journal    
DOI: 10.1016/s2173-5115(08)70258-6     Document Type: Article

References (41)

1. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillaxice report. Arthritis Rheum 2003; 48:2122-7.
2. Vidal CG, Fernandez SR, Lacasa JM, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40:756-9.
3. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001; 69:1847-55.
4. Choy EH, Panayi GS. Citokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344:907-16.
5. Olsen N Stein M. New Drugs for rheumatoid arthritis. N Engl J Med 2004; 350:2167-79.
6. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum 1995; 38:1351-62.
7. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
8. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNF-α) blocking agents and interleukin-1 receptor antagonist (IL-Ira), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004; 63:ii2-ii12.
9. Grupo de Estudos de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia. Consensos para a utilização de terapêutica biológica na Artrite Reumatóide-actualização de Dezembro de 2005. Acta Reumatol Port 2005; 30:349-53.
10. Grupo de Estudo de Artrite Reumatóide da Sociedade Portuguesa de Reumatologia. Análise de 376 doentes com artrite reumatóide submetidos a terapêutica biológica registados na base de dados de agentes biológicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol Port 2005; 30:63-71.
11. Grupo de Consensos Para as Terapêuticas Biológicas na Espondilite Anquilosante da Sociedade Portuguesa de Reumatologia. Consensos sobre a utilização de antagonistas do TNF-alfa na terapêutica da espondilite anquilosante. Acta Reumatol Port 2005; 30:155-9.
12. Grupo de Consensos para as Terapêuticas Biológicas na Espondilite Anquilosante da Sociedade Portuguesa de Reumatologia. Análise de doentes com espondilite anquilosante submetidos a terapêutica biológica registados na base de dados de agentes biológicos da Sociedade Portuguesa de Reumatologia. Acta Reumatol Port 2005; 30: 253-60.
13. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81.
14. http://www.emea.eu.int/humandocs/PDFs/EPAR/Enbrel/014600en6.pdf
15. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41 (Suppl 3):S199-203.
16. Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol 2005; 74(Suppl): 40-7.
17. http://www.emea.eu.int/pdfs/human/opinion/22027005en.pdf.
18. http://www.emea.eu.int/pdfs/human/opinion/20715105en.pdf
19. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus mediotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate therapy. Arthritis Rheum 2006; 54:26-37.
20. Wallis RS, Broder MS, Wong JY, Beenhouwer D. Granulomatosus infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis 2004; 39:1254-5.
21. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford) 2005; 44:714-20.
22. Fonseca JE, Canhão H, Silva C, et al. Tuberculose em doentes reumáticos tratados com antagonistas do factor de necrose tumoral alfa: a experiência portuguesa. Acta Reumatol Port 2006; 31:247-53.
23. Programa nacional de luta contra a tuberculose, Direcção-Geral da Saúde. Tuberculose: ponto da situação em Portugal em 2006, dados preliminares em Março de 2007. http://www.dgs.pt/upload/membro.id/ficheiros/ i009162.pdf
24. Duarte R, Amado J, Lucas H, Sapage M, Comissão de Trabalho de Tuberculose da Sociedade Portuguesa de Pneumologia. Tratamento da tuberculose latente - revisão das normas. Rev Port Pneumol 2006 (in press).
25. Ledingham J, Deighton C. British Society for Rheumatology Standards (SGAWG). Update on the British Society for Rheumatology guidelines for prescribing TNF blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44:157-63.
26. Carmona L, Gómez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis in patients treated with tumour necrosis factor antagonists. Arthritis Rheum 2005; 48:1766-72.
27. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis. 2003;62:791.
28. Bieber J, Kavanough A. Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments. Rheum Dis Clin North Am 2004;30:257-70.
29. Fonseca J E, Lucas H, Canhão H e tal. Recomendações Para diagnóstico e tratamento da tuberculose latente e activa. nas doenças inflamatórias articulares candidatas a tratamento com fármacos inibidores do factor de necrose alfa. Acta Reumatol Port 2006; 31:237-45.
30. Fonseca J E, Lucas H, Canhão H e tal. Recomendações para diagnóstico e tratamento da tuberculose latente e activa. nas doenças inflamatórias articulates candidatas a tratamento com fármacos inibidores do factor de necrose alfa. Rev Port Pneumol 2006;12:603-13.
31. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacteriurn tubeculosis infection and disease in patients due to start anti- TNF-α treatment. Thorax 2005; 60: 800-5.
32. Gardam MA, Keystone EC, Menzies R, et al. Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Infectious Diseases 2003; 3:148-55.
33. Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005; 54: 1360-2.
34. Pamplona P, Carvalho JM. Normas para a quimioprofilaxia da tuberculose. Boletim da Sociedade Portuguesa de Pneumologia 2000; 35:35-41.
35. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: Treatment of Tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
36. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-48.
37. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003; 62:1241-2.
38. Mor A, Bingham CO 3rd, Kishimoto M, et al. Methotrexate combined with isoniazid therapy for latent tuberculosis is well tolerated in rheumatoid arthritis patients: experience from an urban arthritis clinic. Ann Rheum Dis published online 29 Aug 2007.
39. In A tuberculose na viragem do mileńio. Jaime Pina, Ed. Lidel 2000
40. Hsu KH. Thirty years after isoniazid. Its impact on tuberculosis in children and adolescents. JAMA 1984; 251:1283-5.
41. JB Bass Jr, LS Farer, PC Hopewell et al. Treatment of latent tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. Am J Respir Crit Care Med 1994; 149:1359-74.